Nasdaq ctso.

Overview Stock Screener Earnings Calendar Sectors Nasdaq | CTSO U.S.: Nasdaq Cytosorbents Corp. Watch Set a price target alert After Hours Last Updated: Nov 16, …By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2023 results on November 9th which showed strong product revenue growth. 3rd quarter product revenues increased 20% to $7.8 million and grant income decreased 35.9%. The increase in the Euro to U.S. dollar …Read Our Latest Report on Cytosorbents. Cytosorbents Stock Performance. NASDAQ CTSO opened at $1.24 on Thursday. The stock has a market cap of $55.11 million, a P/E ratio of -2.34 and a beta of 0.79.CTSO Latest Pre Market Trades. Select time range to see more trades: Last 100 Trades. Pre-Market Time (ET) Pre-Market Price. Pre-Market Share Volume. 08:27:28. $1.47. 6.

About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...

Find the latest Institutional Holdings data for Cytosorbents Corporation Common Stock (CTSO) at Nasdaq.com. CTSO After-Hours Quotes. Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of ...

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...In this article we will take a look at whether hedge funds think Cytosorbents Corp (NASDAQ:CTSO) is a good investment right now. We check hedge fund and billionaire investor sentiment before ...MONMOUTH JUNCTION, N.J., (PRNewswire) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care ...

As of August 2, 2023, the average one-year price target for Cytosorbents is 8.57. The forecasts range from a low of 5.56 to a high of $16.80. The average price target represents an increase of 155 ...

Cytosorbents Corp (CTSO) has a Smart Score of 5 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.

PRINCETON, N.J., Aug. 14, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood ...MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac ...Get a brief overview of Cytosorbents Corporation financials with all the important numbers. View the latest CTSO income statement, balance sheet, and financial ratios.About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.CTSO | Complete Cytosorbents Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.CTSO - Cytosorbents Corp Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)Are you trading options on Cytosorbents (NASDAQ:CTSO)? View the latest CTSO options chain and put and call options prices at MarketBeat. Skip to main content. S&P 500 4,365.98. DOW 34,095.86. QQQ 369.21. 5 Aerospace & Defense stocks under $5. Trading Experts Call It “The Perfect Tesla Trade” (Ad)

CytoSorbents (NASDAQ:CTSO) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:15 PM.. Here's what investors need to know about the announcement. Earnings. CytoSorbents missed ...PRINCETON, N.J., Aug. 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...The stock price of Cytosorbents Corp (NASDAQ: CTSO) has dropped by -8.59 compared to previous close of 1.28. Despite this, the company has seen a fall of -17.61% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript Is It Worth Investing […]Oct 5, 2023 · About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ... Oct 5, 2023 · About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...

Nov 24, 2023 · CTSO CytoSorbents Corporation Form 8-K - Current report 0001175151 false 0001175151 2023-09-27 2023-09-27 iso4217:USD xbrli:shares ...

Jun 15, 2023 · About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ... TradingView India. View live Cytosorbents Corporation chart to track its stock's price action. Find market predictions, CTSO financials and market news.Find the latest Institutional Holdings data for Cytosorbents Corporation Common Stock (CTSO) at Nasdaq.com.CTSO. --CytoSorbents Corporation, a critical care therapy leader commercializing its CytoSorb ® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and ...CTSO Historical Data. ... Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR ...CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the ...

About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...

Cytosorbents is bordering on breakeven, according to the 4 American Medical Equipment analysts. They expect the company to post a final loss in 2024, before turning a profit of US$5.2m in 2025 ...

CTSO CTSO AFTER HOURS QUOTE CTSO LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... PRINCETON, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Small Cap Growth conference at the …Aug 12, 2021 · About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.PRINCETON, N.J., Jan. 17, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...CTSO CytoSorbents Corporation Form 3 - Initial statement of beneficial ownership of securities. ... (NASDAQ:CTSO) Historical Stock Chart From Oct 2023 to Nov 2023 CytoSorbents (NASDAQ:CTSO)About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, ...Granahan Investment Management LLC increased its stake in Cytosorbents Co. (NASDAQ:CTSO – Free Report) by 3.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and ...MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac ...PRINCETON, N.J., Sept. 9, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Small Cap Growth conference at the Wyndham Grand Jupiter at …May 4, 2023 · By Thomas Kerr, CFA. NASDAQ:CTSO. READ THE FULL CTSO RESEARCH REPORT. CytoSorbents (NASDAQ:CTSO) reported 1st quarter 2023 results on March 2nd with revenue results largely in line with expectations. 1st quarter revenues increased 8.7% to $9.4 million from $8.7 million in the prior year period.

About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...Nasdaq Data Statistical Milestones; Total Returns; Daily Market Statistics; Most ActiveCytosorbents Co. (NASDAQ:CTSO – Free Report) – Stock analysts at Zacks Small Cap decreased their FY2023 EPS estimates for shares of Cytosorbents in a research report issued to clients and investors on Tuesday, November 14th. Zacks Small Cap analyst T. Kerr now expects that the medical research company will post earnings of ($0.61) per share […]Instagram:https://instagram. polished.comstocks for silvereprbxfinity silverdale Cytosorbents Corporation Common Stock (CTSO) Short Interest | Nasdaq. mid-month and end-of-month settlement dates. Nasdaq provides information of company’s and the average days it takes to cover ... top cryptocurrency brokerstop places to buy gold Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Stock analysts at Zacks Small Cap decreased their FY2023 EPS estimates for shares of Cytosorbents in a research report issued to clients and investors on Tuesday, November 14th. Zacks Small Cap analyst T. Kerr now expects that the medical research company will post earnings of ($0.61) per share […]About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, ... banks with immediate debit cards Dec 4, 2023 · In the previous quarter, Cytosorbents (NASDAQ:CTSO) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. CTSO's actual earnings. About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.